Disclosed on May 14, BARBARA DESOER, Director at DaVita (NYSE:DVA), executed a substantial insider sell as per the latest SEC filing.
What Happened: According to a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday, DESOER sold 5,030 shares of DaVita. The total transaction value is $698,214.
DaVita’s shares are actively trading at $136.34, experiencing a down of 0.49% during Wednesday’s morning session.
All You Need to Know About DaVita
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Unraveling the Financial Story of DaVita
Revenue Growth: Over the 3 months period, DaVita showcased positive performance, achieving a revenue growth rate of 6.89% as of 31 March, 2024. This reflects a substantial increase in the company’s top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Holistic Profitability Examination:
Gross Margin: The company sets a benchmark with a high gross margin of 32.29%, reflecting superior cost management and profitability compared to its peers.
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 2.73, DaVita showcases strong earnings per share.
Debt Management: With a high debt-to-equity ratio of 12.79, DaVita faces challenges in effectively managing its debt levels, indicating potential financial strain.
Exploring Valuation Metrics Landscape:
Price to Earnings (P/E) Ratio: DaVita’s P/E ratio of 15.53 is below the industry average, suggesting the stock may be undervalued.
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 1.03, the stock presents an attractive…
Click Here to Read the Full Original Article at Cryptocurrencies Feed…
